Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
S-1 plus oxaliplatin has been proved better than S-1 alone for stage II or III gastric
cancer.
Docetaxel also showed excellent efficacy with S-1 in the postoperative setting for stage III
gastric cancer.
This trial is designed to investigate the efficacy and safety of S-1 plus docetaxel versus
S-1 plus oxalipltin as adjuvant chemotherapy after D2 resection in stage II / III gastric
cancer.